Literature DB >> 11817515

Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety.

Paola Rocca1, Elena Cocuzza, Livio Marchiaro, Filippo Bogetto.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the long-term efficacy, safety and tolerability of donepezil in the treatment of Alzheimer's disease (AD).
METHODS: Twenty-five patients (15 females and 10 males) with mild to moderate AD, according to DSM IV criteria, were recruited in the study. The principal efficacy measures were Alzheimer Disease Assessment Scale-cognitive subscale score (ADAS-cog), Mini Mental State Examination (MMSE) and Physical Self-Maintenance Scale (PSMS). Patients were treated with donepezil 5 mg/day for 1 month, after which an increase to 10 mg/day was encouraged. Evaluations were carried out prior to the start of the treatment and every 3 months for a period of 1 year.
RESULTS: A significant improvement from baseline score of cognitive performances was seen through Week 24. Beginning with Week 36, performances declined relative to baseline, indicating continued disease progression.
CONCLUSIONS: Donepezil improved cognition and global functioning and was well tolerated especially considered the long duration of the observation period.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11817515     DOI: 10.1016/s0278-5846(01)00283-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

Review 1.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 2.  Non-cholinergic strategies for treating and preventing Alzheimer's disease.

Authors:  P Murali Doraiswamy
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Donepezil for dementia due to Alzheimer's disease.

Authors:  Jacqueline S Birks; Richard J Harvey
Journal:  Cochrane Database Syst Rev       Date:  2018-06-18

4.  Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study.

Authors:  Yu San Chang; Yu Hsuan Wu; Chin Jen Wang; Shu Hui Tang; Hsiang Lan Chen
Journal:  BMC Neurosci       Date:  2018-06-22       Impact factor: 3.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.